Pulse Biosciences to Present Innovative nsPFA Technology at AF Symposium 2025

Pulse Biosciences to Showcase Groundbreaking nsPFA Technology at AF Symposium 2025

Pulse Biosciences, Inc. is set to present its innovative Nanosecond Pulsed Field Ablation™ (nsPFA™) technology at the upcoming 30th Annual AF Symposium 2025, scheduled for January 16-18 in Boston. This event represents a significant platform for the company to demonstrate its latest advancements in cardiac treatment technology. The spotlight will be on the nsPFA 360° catheter, which will be featured in a late-breaking science session and a live case demonstration alongside the Abbott Ensite X 3D Mapping System. This collaboration underlines the growing trend towards integrating advanced mapping technologies with cutting-edge ablation techniques, offering a glimpse into the future of cardiac care.

Co-Chairman Paul LaViolette expresses enthusiasm about the company’s progress, particularly since he joined the board last year. He highlights the substantial advancements in product development and clinical evidence surrounding the nsPFA 360° Cardiac Catheter. The upcoming symposium is set to include key presentations that can significantly impact the company’s trajectory in the healthcare sector. Notably, on January 17, Dr. Vivek Reddy will share findings from a feasibility study involving the first 30 patients treated with the catheter, showcasing its clinical effectiveness and safety. This presentation is anticipated to draw considerable attention from the medical community, potentially influencing future adoption and research directions.

The live case demonstration conducted by Dr. Petr Neuzil on January 18 will further illustrate the catheter's capabilities, particularly in pulmonary vein isolation—a critical procedure for patients with atrial fibrillation. This demonstration, coupled with the integration of 3D navigation technology, is expected to provide compelling evidence of the catheter's efficiency and effectiveness. Pulse Biosciences aims to take a significant step forward by initiating a pivotal U.S. Investigational Device Exemption (IDE) clinical study for the catheter by mid-2025, reinforcing its commitment to advancing healthcare solutions that enhance patient outcomes.

In addition to the symposium, Pulse Biosciences is dedicated to innovating healthcare with its CellFX® nsPFA™ technology, which uniquely non-thermally eliminates cells while preserving surrounding tissue. This method presents vast potential applications in treating various medical conditions, particularly atrial fibrillation, which poses significant healthcare challenges. The company's mission remains focused on improving patient quality of life and pioneering advancements within the clinical community.

As Pulse Biosciences prepares for this pivotal event, the anticipation surrounding its nsPFA technology reflects the broader trends in cardiac care innovation, emphasizing the importance of collaboration and evidence-based practices in the evolving landscape of medical technology.